IGF-1 and Bone Loss in Women with Anorexia Nervosa

神经性厌食症女性的 IGF-1 和骨质流失

基本信息

  • 批准号:
    8063348
  • 负责人:
  • 金额:
    $ 9.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-14 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary Severe osteopenia is a prevalent complication of anorexia nervosa (AN), affecting over half of all women with this disease. Loss of bone mass occurs frequently and is often permanent. Reduction of bone mineral density (BMD) by at least 1.0 SD at one or more skeletal sites occurs in over 90% of subjects and by at least 2.5 SD in over 1/3 of subjects. Moreover, this reduction is associated with a 30% prevalence of fractures. Although AN affects from 0.5-1.0% of college- age women, no successful therapeutic interventions have been developed to prevent bone loss or increase bone mass in this young population. Our preliminary data demonstrate severe bone structural abnormalities as well, including markedly reduced trabecular thickness, trabecular number and bone volume and increased trabecular separation. Bone loss in AN is characterized by reduced bone formation coupled with increased bone resorption. Anorexia nervosa results in growth hormone (GH) resistance and resultant severe insulin-like growth factor 1 (IGF-1) deficiency due to undernutrition. This acquired deficiency of IGF-1, an endogenous bone trophic factor, is an important determinant of decreased bone formation in this population. IGF-1 is known to have anabolic actions on bone, and we have demonstrated increases in bone formation and BMD in women with AN with administration of recombinant IGF-1 (rhIGF-1). However, despite increasing bone formation, bone resorption remains high, and a therapy to effectively decrease resorption in the state of undernutrition is needed. Bisphosphonates are well established to decrease bone resorption and improve BMD in severely osteopenic postmenopausal women, and our preliminary data demonstrate significant increases in BMD in women with AN. Recent data using anabolic and anti-resorptive therapies have suggested that sequential therapy may result in greater gains in BMD that concurrently administered combination therapy. There are no data investigating such therapeutic strategies in this population, in whom there are no established therapies. We will test the hypothesis that a strategy to administer an anabolic therapy, rhIGF-1, for six months followed by a bisphosphonate, risedronate, for six months will increase bone mass and improve microarchitecture in women with anorexia nervosa.
项目摘要 严重骨质减少是神经性厌食症(AN)的常见并发症, 所有患有这种疾病的女性。骨质流失经常发生,而且往往是永久性的。 一个或多个骨骼部位的骨矿物质密度(BMD)降低至少1.0 SD 在超过90%的受试者中,超过1/3的受试者中至少2.5 SD。此外,这种减少 与30%的骨折患病率有关虽然AN影响从0.5-1.0%的大学- 对于年龄较大的女性,还没有成功的治疗干预措施来预防骨质流失。 或者增加年轻人的骨量。我们的初步数据显示 结构异常,包括骨小梁厚度明显减少, 数量和骨体积以及骨小梁分离增加。AN中的骨丢失是 其特征在于减少的骨形成伴随增加的骨吸收。厌食 神经型糖尿病导致生长激素(GH)抵抗和严重的胰岛素样生长 因子1(IGF-1)缺乏症,由于营养不良。这种IGF-1的获得性缺乏, 内源性骨营养因子是骨形成减少的重要决定因素, 这个人口。已知IGF-1对骨骼具有合成代谢作用,我们已经证明 给予重组蛋白后AN女性的骨形成和骨密度增加 IGF-1(rhIGF-1)。然而,尽管骨形成增加,骨吸收仍然很高, 需要一种在营养不良状态下有效减少再吸收的疗法。 双膦酸盐已被公认可减少骨吸收并改善骨密度, 严重骨质疏松的绝经后妇女,我们的初步数据表明, 增加女性的骨密度。使用合成代谢和抗吸收疗法的最新数据 表明序贯治疗可能会导致骨密度增加, 给予联合治疗。目前尚无研究此类治疗策略的数据 在这个人群中,没有既定的治疗方法。我们将检验这个假设, 一种策略,给予合成代谢疗法,rhIGF-1,为期六个月,随后是 双膦酸盐,利塞膦酸盐,六个月将增加骨量,改善 神经性厌食症妇女的微结构。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANNE KLIBANSKI其他文献

ANNE KLIBANSKI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANNE KLIBANSKI', 18)}}的其他基金

The Role of lncRNA MEG3 in Clinically Non-functioning Pituitary Adenomas
lncRNA MEG3 在临床无功能垂体腺瘤中的作用
  • 批准号:
    9215659
  • 财政年份:
    2016
  • 资助金额:
    $ 9.21万
  • 项目类别:
Hormonal Factors in the Treatment of Anorexia Nervosa
治疗神经性厌食症的激素因素
  • 批准号:
    8599482
  • 财政年份:
    2010
  • 资助金额:
    $ 9.21万
  • 项目类别:
Hormonal Factors in the Treatment of Anorexia Nervosa
治疗神经性厌食症的激素因素
  • 批准号:
    8401158
  • 财政年份:
    2010
  • 资助金额:
    $ 9.21万
  • 项目类别:
PHYSIOLOGIC GH ADMIN ON CARDIOVASCULAR RISK MARKERS IN WOMEN WITH GH DEFICIENCY
GH 生理学管理对 GH 缺乏女性心血管风险标志物的影响
  • 批准号:
    7731234
  • 财政年份:
    2008
  • 资助金额:
    $ 9.21万
  • 项目类别:
THE EFFECT OF ANOREXIA NERVOSA ON PEAK BONE MASS
神经性厌食症对峰值骨量的影响
  • 批准号:
    7731313
  • 财政年份:
    2008
  • 资助金额:
    $ 9.21万
  • 项目类别:
OSTEOPENIA IN ANOREXIA NERVOSA
神经性厌食症中的骨质减少
  • 批准号:
    7731309
  • 财政年份:
    2008
  • 资助金额:
    $ 9.21万
  • 项目类别:
HORMONE DYNAMICS AND BONE MINERAL DENSITY IN ANOREXIA NERVOSA VS HYPOTHALAMIC
神经性厌食症与下丘脑性厌食症的激素动态和骨矿物质密度
  • 批准号:
    7731326
  • 财政年份:
    2008
  • 资助金额:
    $ 9.21万
  • 项目类别:
CLINICAL TRIAL: THE EFFECTS OF TESTOSTERONE AND ACTONEL ON BONE DENSITY IN ANORE
临床试验:睾酮和 Actonel 对肛门骨密度的影响
  • 批准号:
    7731240
  • 财政年份:
    2008
  • 资助金额:
    $ 9.21万
  • 项目类别:
NEUROENDOCRINE FACTORS IN ADOLESCENT OBESITY
青少年肥胖的神经内分泌因素
  • 批准号:
    7731256
  • 财政年份:
    2008
  • 资助金额:
    $ 9.21万
  • 项目类别:
CLINICAL TRIAL: EFFECTS OF SUPRAPHYSIOLOGICAL RHGH ON BONE METABOLISM IN ANOREXI
临床试验:超生理学 RHGH 对厌食症患者骨代谢的影响
  • 批准号:
    7731266
  • 财政年份:
    2008
  • 资助金额:
    $ 9.21万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 9.21万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 9.21万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 9.21万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 9.21万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 9.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 9.21万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 9.21万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 9.21万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 9.21万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 9.21万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了